Reuters gives insight into how Pfizer, Moderna is reaping billions from COVID-19 vaccine booster market

Reuters took readers on a deep dive into how drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come. The companies have said they expect that fully inoculated people will need an extra dose to maintain protection and to fend off new variants. Now a growing list of governments have decided to offer booster doses to older citizens or people with weak immune systems in the face of the fast-spreading Delta variant. 

Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: Americas
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Major Global Story
Sign up for email updates

Sign up for email updates